Oppenheimer Downgrades Portola Pharmaceuticals to Perform, Lowers Price Target to $17

Oppenheimer downgrades Portola Pharmaceuticals (NASDAQ:PTLA) from Outperform to Perform and lowers the price target from $40 to $17.

Benzinga · 01/10/2020 12:35

Oppenheimer downgrades Portola Pharmaceuticals (NASDAQ:PTLA) from Outperform to Perform and lowers the price target from $40 to $17.